1. Quantitative evaluation of in vivo vital-dye fluorescence endoscopic imaging for the detection of Barrett's-associated neoplasia.

    Journal of Biomedical Optics 20(5):56002 (2015) PMID 25950645 PMCID PMC4423850

    Current imaging tools are associated with inconsistent sensitivity and specificity for detection of Barrett's-associated neoplasia. Optical imaging has shown promise in improving the classification of neoplasia in vivo. The goal of this pilot study was to evaluate whether in vivo vital dye fluor...
  2. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.

    PNAS 111(51):18261 (2014) PMID 25489091 PMCID PMC4280633

    The androgen receptor (AR) is a key driver of prostate cancer (PC), even in the state of castration-resistant PC (CRPC) and frequently even after treatment with second-line hormonal therapies such as abiraterone and enzalutamide. The persistence of AR activity via both ligand-dependent and ligan...
  3. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.

    PNAS 111(51):18261 (2014) PMID 25489091 PMCID PMC4280633

    The androgen receptor (AR) is a key driver of prostate cancer (PC), even in the state of castration-resistant PC (CRPC) and frequently even after treatment with second-line hormonal therapies such as abiraterone and enzalutamide. The persistence of AR activity via both ligand-dependent and ligan...
  4. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.

    PNAS 111(51):18261 (2014) PMID 25489091 PMCID PMC4280633

    The androgen receptor (AR) is a key driver of prostate cancer (PC), even in the state of castration-resistant PC (CRPC) and frequently even after treatment with second-line hormonal therapies such as abiraterone and enzalutamide. The persistence of AR activity via both ligand-dependent and ligan...
  5. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.

    PNAS 111(51):18261 (2014) PMID 25489091

    The androgen receptor (AR) is a key driver of prostate cancer (PC), even in the state of castration-resistant PC (CRPC) and frequently even after treatment with second-line hormonal therapies such as abiraterone and enzalutamide. The persistence of AR activity via both ligand-dependent and ligan...
  6. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.

    PNAS 111(51):18261 (2014) PMID 25489091 PMCID PMC4280633

    The androgen receptor (AR) is a key driver of prostate cancer (PC), even in the state of castration-resistant PC (CRPC) and frequently even after treatment with second-line hormonal therapies such as abiraterone and enzalutamide. The persistence of AR activity via both ligand-dependent and ligan...
  7. The use of endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of thyroid lesions.

    BMC Endocrine Disorders 14:88 (2014) PMID 25416021 PMCID PMC4247684

    Non-palpable thyroid nodules can be difficult to access by conventional ultrasound-guided fine needle aspiration, particularly when they are intrathoracic. Many of these patients are subject to multiple follow up scans or invasive diagnostic procedures such as mediastinoscopy or surgical resecti...
  8. The use of endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of thyroid lesions.

    BMC Endocrine Disorders 14:88 (2014) PMID 25416021 PMCID PMC4247684

    Non-palpable thyroid nodules can be difficult to access by conventional ultrasound-guided fine needle aspiration, particularly when they are intrathoracic. Many of these patients are subject to multiple follow up scans or invasive diagnostic procedures such as mediastinoscopy or surgical resecti...
  9. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.

    International Journal of Gynecological Cancer 23(5):815 (2013) PMID 23669443 PMCID PMC3760786

    Most patients with epithelial ovarian cancer achieve a complete clinical remission (CCR) with normal CA-125 but will still relapse and die from their disease. The present study was designed to determine whether CA-125 levels before, during, and after primary treatment provide prognostic informat...
  10. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.

    International Journal of Gynecological Cancer 23(5):815 (2013) PMID 23669443 PMCID PMC3760786

    Most patients with epithelial ovarian cancer achieve a complete clinical remission (CCR) with normal CA-125 but will still relapse and die from their disease. The present study was designed to determine whether CA-125 levels before, during, and after primary treatment provide prognostic informat...
  11. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency.

    Breast Cancer Research (Online Edition) 15(5):R77 (2013) PMID 24008095 PMCID PMC4053576

    We hypothesized that cells present in normal tissue that bear cancer stem cell markers may represent a cancer cell of origin or a microenvironment primed for tumor development, and that their presence may correlate with the clinically defined subtypes of breast cancer that show increased tumorig...
  12. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency.

    Breast Cancer Research (Online Edition) 15(5):R77 (2013) PMID 24008095 PMCID PMC4053576

    We hypothesized that cells present in normal tissue that bear cancer stem cell markers may represent a cancer cell of origin or a microenvironment primed for tumor development, and that their presence may correlate with the clinically defined subtypes of breast cancer that show increased tumorig...
  13. CD133 expression associated with poor prognosis in ovarian cancer.

    Modern Pathology 25(3):456 (2012) PMID 22080056 PMCID PMC3855345

    As a putative marker for cancer stem cells in human malignant tumors, including ovarian cancer, CD133 expression may define a tumor-initiating subpopulation of cells and is associated with the clinical outcome of patients. However, at this time its clinical significance in ovarian cancer remains...
  14. CD133 expression associated with poor prognosis in ovarian cancer.

    Modern Pathology 25(3):456 (2012) PMID 22080056 PMCID PMC3855345

    As a putative marker for cancer stem cells in human malignant tumors, including ovarian cancer, CD133 expression may define a tumor-initiating subpopulation of cells and is associated with the clinical outcome of patients. However, at this time its clinical significance in ovarian cancer remains...
  15. CD133 expression associated with poor prognosis in ovarian cancer.

    Modern Pathology 25(3):456 (2012) PMID 22080056 PMCID PMC3855345

    As a putative marker for cancer stem cells in human malignant tumors, including ovarian cancer, CD133 expression may define a tumor-initiating subpopulation of cells and is associated with the clinical outcome of patients. However, at this time its clinical significance in ovarian cancer remains...
  16. Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma.

    Histopathology 59(4):619 (2011) PMID 22014043

    The aim of this study was to review the clinicopathological characteristics of neuroendocrine tumours (NETs) metastasizing to the breast, in order to identify features that could be useful in distinguishing these metastatic lesions from primary breast neoplasms. Eighteen metastatic NETs in the b...
  17. Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma.

    Histopathology 59(4):619 (2011) PMID 22014043

    The aim of this study was to review the clinicopathological characteristics of neuroendocrine tumours (NETs) metastasizing to the breast, in order to identify features that could be useful in distinguishing these metastatic lesions from primary breast neoplasms. Eighteen metastatic NETs in the b...
  18. AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma.

    Modern Pathology 24(6):836 (2011) PMID 21441901 PMCID PMC3152794

    Aurora kinase A (AURKA), a serine/threonine kinase, has been shown to regulate the cell cycle checkpoint and maintain genomic integrity. AURKA is overexpressed in various carcinomas. Breast cancer 2, early onset (BRCA2) has an important role in maintaining genomic stability and acts as a tumor s...
  19. AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma.

    Modern Pathology 24(6):836 (2011) PMID 21441901 PMCID PMC3152794

    Aurora kinase A (AURKA), a serine/threonine kinase, has been shown to regulate the cell cycle checkpoint and maintain genomic integrity. AURKA is overexpressed in various carcinomas. Breast cancer 2, early onset (BRCA2) has an important role in maintaining genomic stability and acts as a tumor s...
  20. AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma.

    Modern Pathology 24(6):836 (2011) PMID 21441901 PMCID PMC3152794

    Aurora kinase A (AURKA), a serine/threonine kinase, has been shown to regulate the cell cycle checkpoint and maintain genomic integrity. AURKA is overexpressed in various carcinomas. Breast cancer 2, early onset (BRCA2) has an important role in maintaining genomic stability and acts as a tumor s...